Literature DB >> 6785348

A human T lymphocyte differentiation marker defined by monoclonal antibodies that block E-rosette formation.

F D Howard, J A Ledbetter, J Wong, C P Bieber, E B Stinson, L A Herzenberg.   

Abstract

A new human T cell surface antigen, Leu-5, has been defined using a set of monoclonal antibodies that block rosette formation between T lymphocytes and sheep erythrocytes (SRBC). Four antibodies obtained from 2 different fusions using 2 immunized mouse strains all reacted with the same antigen. All these antibodies gave identical quantitative immunofluorescence (FACS) profiles, all gave the same staining profiles and intensities when used singly or in combinations, and all precipitated the same molecule. The antigen is a single polypeptide chain, 40,000 to 50,000 Mr, and is found on all thymocytes, peripheral T cells, and some null cells, but not on B cells. Leu-5 is a differentiation antigen that decreases in density as thymocytes mature to peripheral T lymphocytes. Thus, the Leu-5+ subpopulations ranked in order of decreasing Leu-5 density are: a subpopulation of subcapsular thymocytes greater than cortical and medullary thymocytes greater than peripheral T cells (cytotoxic/suppressor subset) greater than peripheral T cells (helper/inducer subset). The density distribution pattern of Leu-5 parallels the relative affinity of thymocytes and peripheral T lymphocytes for SRBC. We suggest that Leu-5 is either identical to or closely associated with the human T lymphocyte receptor for SRBC.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6785348

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  50 in total

1.  Documentation of immune profile of microglia through cell surface marker study in glioma model primed by a novel cell surface glycopeptide T11TS/SLFA-3.

Authors:  Z Begum; A Ghosh; S Sarkar; J Mukherjee; M Mazumdar; P Sarkar; S Chaudhuri
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

2.  Functional surface structures on human natural killer cells.

Authors:  R E Schmidt; T Hercend; S F Schlossman; J Ritz
Journal:  Klin Wochenschr       Date:  1985-12-02

3.  Expression of T3 and T11 determinants on human peripheral lymphocytes as analysed by the indirect antiglobulin rosetting reaction (IARR) and indirect immunofluorescence.

Authors:  D G Haegert
Journal:  Clin Exp Immunol       Date:  1985-09       Impact factor: 4.330

4.  Costimulatory signal provided by a B-lymphoblastoid cell line and its Ia-negative variant.

Authors:  H Reiser; B Benacerraf
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

Review 5.  T-cell clones and T-cell receptors.

Authors:  F W Fitch
Journal:  Microbiol Rev       Date:  1986-03

6.  In situ immunocytochemical staining of cell colonies growing in plasma clot.

Authors:  A Bontadini; M Gobbi; A Dinota; P L Tazzari; M T Rivano; S Pileri
Journal:  Histochemistry       Date:  1988

7.  Expression of the T-cell surface molecule CD2 and an epitope-loss CD2 mutant to define the role of lymphocyte function-associated antigen 3 (LFA-3) in T-cell activation.

Authors:  B E Bierer; A Peterson; J Barbosa; B Seed; S J Burakoff
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

Review 8.  The role of leukocyte adhesion molecules in cellular interactions: implications for the pathogenesis of inflammatory synovitis.

Authors:  B F Haynes; L P Hale; S M Denning; P T Le; K H Singer
Journal:  Springer Semin Immunopathol       Date:  1989

9.  Monoclonal antibodies specific for murine CD2 reveal its presence on B as well as T cells.

Authors:  H Yagita; T Nakamura; H Karasuyama; K Okumura
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

10.  Intracellular mediators regulate CD2 lateral diffusion and cytoplasmic Ca2+ mobilization upon CD2-mediated T cell activation.

Authors:  S J Liu; W C Hahn; B E Bierer; D E Golan
Journal:  Biophys J       Date:  1995-02       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.